Assembly Biosciences (ASMB) Stock: Buy, Sell, or Hold?
ASMB - Assembly Biosciences, Inc
$20.28
-0.18 (-0.88%)
▼
5d:
-1.41%
30d:
-15.39%
90d:
-20.63%
BUY
MODERATE Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 09, 2026
16d
Get Alerted When ASMB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ASMB shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ASMB shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ASMB is currently trading at $20.28, which is considered oversold relative to its 30-day fair value range of $20.99 to $25.21.
Technical Outlook: Technically, ASMB is showing sideways momentum. The price is currently testing key support at $19.94. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ASMB scores 67/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $52.00 (+156.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ASMB is showing sideways momentum. The price is currently testing key support at $19.94. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ASMB scores 67/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $52.00 (+156.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$20.99 -
$25.21
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (67/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 156.4% below Wall St target ($52.00)
- BULLISH: Bottoming setup score 67/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$20.99 -
$25.21
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$19.94
Resistance Level
$23.83
Current Trend
Sideways
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.88
Wall Street Target
$52.00
(+156.4%)
Revenue Growth (YoY)
38.9%
Profit Margin
-0.1%
Share & Embed Analysis
Last updated: October 23, 2026 8:58 AM ET
Data refreshes hourly during market hours. Next update: 9:58 AM
Data refreshes hourly during market hours. Next update: 9:58 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ASMB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$295 | 62 BUY |
|
REGN
Regeneron Pharmaceutical… |
BUY
28 analysts |
$864 | 44 HOLD |
|
PRAX
Praxis Precision Medicin… |
STRONG BUY
20 analysts |
$650 | 61 BUY |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
17 analysts |
$36 | 57 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
STRONG BUY
20 analysts |
$31 | 66 BUY |
